Literature DB >> 10480903

Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation.

V Ollendorff1, G Guasch, D Isnardon, R Galindo, D Birnbaum, M J Pébusque.   

Abstract

The t(8;13) translocation found in a rare type of stem cell myeloproliferative disorder generates a constitutively activated tyrosine kinase containing N-terminal sequence encoded by the FIM gene linked to the FGFR1 kinase domain. Here we have further characterized FIM and FIM-FGFR1 proteins. Firstly, we have studied their respective subcellular localization. We show that FIM has nuclear and nucleolar localization, whereas FIM-FGFR1 is mainly cytoplasmic. Within the nucleolus, FIM colocalizes with the upstream binding factor in interphasic cells, indicating that FIM may be involved in the regulation of rRNA transcription. We demonstrate that the targetting of FIM to the nucleus depends upon its C-terminal region, which is absent in the cytoplasmic FIM-FGFR1 protein. Secondly, we demonstrate that FIM-FGFR1 has constitutive dimerization capability mediated by the FIM N-terminal sequences. Finally, we show that FIM-FGFR1 promotes survival of pro-B Ba/F3 cells after interleukin-3 withdrawal, whereas ligand-activated FGFR1 induced not only cell survival but also interleukin-3 independence. Taken together, these results indicate that FIM-FGFR1 is activated by dimerization as a cytoplasmic kinase and suggest that FIM-FGFR1 partially signals through the FGFR1 pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480903     DOI: 10.1074/jbc.274.38.26922

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

3.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

Authors:  G Guasch; V Ollendorff; J P Borg; D Birnbaum; M J Pébusque
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 5.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

6.  14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.

Authors:  Shaozhong Dong; Sumin Kang; Ting-Lei Gu; Sean Kardar; Haian Fu; Sagar Lonial; Hanna Jean Khoury; Fadlo Khuri; Jing Chen
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

7.  Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Authors:  Christina B Duckworth; Linsheng Zhang; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.